NEW YORK (GenomeWeb News) – Bioinformatics company Cartagenia today announced it received a Canadian medical establishment license for its Cartagenia Bench platform.

The platform is a cloud-based software product for the analysis, interpretation, reporting, and sharing of genomic variants in routine clinical diagnostics. It is CE marked, registered with the US Food and Drug Administration as an exempt Class I Medical Device, and registered in Europe also as a Class I Medical Device, Cartagenia said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.